Antithrombotics

Cilostarol Effective, Safer Than Ticlopidine

Published in Blood Weekly, February 10th, 2000

Cilostarol with aspirin is an effective antithrombotic regimen and is safer than the standard ticlopidine with aspirin, researchers say.

Triclopidine, frequently administered as an antithrombotic after coronary stenting, can elicit side effects such as neutropenia or thrombocytopenia. To test the efficacy of cilostarol as an alternative to triclopidine, Y. S. Yoon and colleagues at Yonsei University, South Korea, randomly administered cilostarol with aspirin (C+A) or triclopidine with aspirin (T+A) to 300 patients, who each received 1 of the drug combinations 2 days prior to stenting.

The researchers found that 1.4% of the C+A group and 2.0% of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2000-02-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry